Effect of oral ketoconazole on first-pass effect of nifedipine after oral administration in dogs.

No abstract is available for this paper.

• Publication year

  2002

• Venue

  Journal of Pharmacy and Science

• Publication date

  2002-03-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1002/JPS.10086PMID 11920771
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Effect of multiple dosing of ketoconazole on pharmacokinetics of midazolam, a cytochrome P-450 3A substrate in beagle dogs.

  2002cited by this paper
• Differentiation of intestinal and hepatic cytochrome P450 3A activity with use of midazolam as an in vivo probe: Effect of ketoconazole

  1999cited by this paper
• Intestinal MDR transport proteins and P-450 enzymes as barriers to oral drug delivery.

  1999cited by this paper
• Effects of ketoconazole on the intestinal metabolism, transport and oral bioavailability of K02, a novel vinylsulfone peptidomimetic cysteine protease inhibitor and a P450 3A, P-glycoprotein dual substrate, in male Sprague-Dawley rats.

  1998cited by this paper
• Prediction of pharmacokinetic alterations caused by drug-drug interactions: metabolic interaction in the liver.

  1998cited by this paper
• Metabolism of halofantrine to its equipotent metabolite, desbutylhalofantrine, is decreased when orally administered with ketoconazole.

  1998cited by this paper
• Grapefruit juice increases felodipine oral availability in humans by decreasing intestinal CYP3A protein expression.

  1997cited by this paper
• Tacrolimus oral bioavailability doubles with coadministration of ketoconazole

  1997cited by this paper
• Midazolam Hydroxylation by Human Liver Microsomes In Vitro: Inhibition by Fluoxetine, Norfluoxetine, and by Azole Antifungal Agents

  1996cited by this paper
• Comparative studies of drug-metabolizing enzymes in dog, monkey, and human small intestines, and in Caco-2 cells.

  1996cited by this paper
• The effects of ketoconazole on the intestinal metabolism and bioavailability of cyclosporine

  1995cited by this paper
• Metabolism of the immunosuppressant tacrolimus in the small intestine: cytochrome P450, drug interactions, and interindividual variability.

  1995cited by this paper
• Metabolism of terfenadine associated with CYP3A(4) activity in human hepatic microsomes.

  1995cited by this paper
• Sensitive high-performance liquid chromatographic assay for nifedipine in human plasma utilizing ultraviolet detection.

  1994cited by this paper
• Oral azole drugs as systemic antifungal therapy.

  1994cited by this paper
• Disposition of Azole Antifungal Agents. I. Nonlinearities in Ketoconazole Clearance and Binding in Rat Liver

  1993cited by this paper
• Cyclosporin A drug interactions. Screening for inducers and inhibitors of cytochrome P-450 (cyclosporin A oxidase) in primary cultures of human hepatocytes and in liver microsomes.

  1990cited by this paper
• Identification of glucocorticoid-inducible cytochromes P-450 in the intestinal mucosa of rats and man.

  1987cited by this paper
• Clinical Pharmacokinetics of Verapamil, Nifedipine and Diltiazem

  1986cited by this paper
• Pharmacokinetics of ketoconazole administered intravenously to dogs and orally as tablet and solution to humans and dogs.

  1986cited by this paper
• Characterization of rat and human liver microsomal cytochrome P-450 forms involved in nifedipine oxidation, a prototype for genetic polymorphism in oxidative drug metabolism.

  1986cited by this paper
• A pharmacokinetic analysis program (multi) for microcomputer.

  1981cited by this paper
• Interspecies variation in liver weight, hepatic blood flow, and antipyrine intrinsic clearance: Extrapolation of data to benzodiazepines and phenytoin

  1980cited by this paper

• Impact of Cytochrome P450 Enzymes on the Phase I Metabolism of Drugs

  2023cites this paper
• Improved solubility and permeability of both nifedipine and ketoconazole based on coamorphous formation with simultaneous dissolution behavior

  2021cites this paper
• Comparing Potential Drug–Drug Interactions in Companion Animal Medications Using Two Electronic Databases

  2021cites this paper
• Effects of Cilostazol on the Pharmacokinetics of Nifedipine After Oral and Intravenous Administration in Rats

  2017cites this paper
• Pharmacokinetic Drug Interaction between Nifedipine and Gliclazide

  2016cites this paper
• Possible drug–drug interaction in dogs and cats resulted from alteration in drug metabolism: A mini review

  2015cites this paper
• Effects of HMG-CoA reductase inhibitors on the pharmacokinetics of nifedipine in rats: Possible role of P-gp and CYP3A4 inhibition by HMG-CoA reductase inhibitors

  2015cites this paper
• Utility of cryopreserved hepatocytes suspended in serum to predict hepatic clearance in dogs and monkeys.

  2014cites this paper
• Effects of pioglitazone on the pharmacokinetics of nifedipine and its main metabolite, dehydronifedipine, in rats

  2014cites this paper
• Novel pre-clinical methodologies for pharmacokinetic drug–drug interaction studies: spotlight on “humanized” animal models

  2014cites this paper
• In vitro to in vivo extrapolation and physiologically based modeling of cytochrome P450 mediated metabolism in beagle dog gut wall and liver.

  2013cites this paper
• Effects of ketoconazole and rifampicin on the pharmacokinetics of GLS4, a novel anti-hepatitis B virus compound, in dogs

  2013cites this paper
• The Effects on Metabolic Clearance when Administering a Potent CYP3A Autoinducer with the Prototypic CYP3A Inhibitor, Ketoconazole

  2012cites this paper
• In vitro and in vivo small intestinal metabolism of CYP3A and UGT substrates in preclinical animals species and humans: species differences

  2011cites this paper
• Examination of CYP3A and P-glycoprotein-mediated drug-drug interactions using animal models.

  2010cites this paper
• The pharmacokinetics of ketoconazole and its effects on the pharmacokinetics of midazolam and fentanyl in dogs.

  2010cites this paper
• Significance of protein binding in pharmacokinetics and pharmacodynamics.

  2010cites this paper
• Inhibitory effects of ketoconazole, cimetidine and erythromycin on hepatic CYP3A activities in cats.

  2009cites this paper
• Species differences in in vitro and in vivo small intestinal metabolism of CYP3A substrates.

  2008cites this paper
• Development of an in vivo rat screen model to predict pharmacokinetic interactions of CYP3A4 substrates

  2007cites this paper
• Multiple oral dosing of ketoconazole increases dog exposure to ivermectin.

  2007cites this paper
• Plasma pharmacokinetics and CYP3A12-dependent metabolism of c-kit inhibitor imatinib in dogs

  2007cites this paper
• In vivo animal models for investigating potential CYP3A- and Pgp-mediated drug-drug interactions.

  2006cites this paper
• Cytochrome P450 and its role in veterinary drug interactions.

  2006cites this paper
• DETERMINATION OF THE ENZYME(S) INVOLVED IN THE METABOLISM OF AMIODARONE IN LIVER AND INTESTINE OF RAT: THE CONTRIBUTION OF CYTOCHROME P450 3A ISOFORMS

  2006influential citation
• Enhancement of Nifedipine-Induced Gingival Overgrowth by Concomitant Ketoconazole in Rats

  2005cites this paper
• Multiple oral dosing of ketoconazole influences pharmacokinetics of quinidine after intravenous and oral administration in beagle dogs.

  2004cites this paper